Robust & reliable neoantigen prediction to empower the next generation cancer immunotherapies.
OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy.
OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in a clinically actionable time-frame.
OncoImmunity AS is a privately held company founded in 2014 and is based in Oslo, Norway and Cambrigde, MA USA. The company is backed by capital financing from both life science and technology and artificial intelligence/software specialist investors, as well as a number of strong and highly experienced and renowned private investors.
Radforsk is the lead investor and has vast experience and a strong track record with developing early stage research-based companies in the immune-oncology sector. Radforsk works hands-on in directing OncoImmunity toward its success. StartupLab/Founders Fund, Grotmol Solutions, Geveran Trading Co. Ltd., MP Pensjon, Sundt and the Norwegian Cancer Society are among the other investors. The full list of the shareholders can be found here.
For investor relations and more information, please contact the OncoImmunity Chairman of the Board, Anders Tuv.
OncoImmunity has assembled a growing and experienced multidisciplinary team of bioinformaticians, software-engineers and data scientists with machine-learning expertise.
A bionformatics company governed by seasoned biotechnology and software directors.
A development environment deeply immersed in the combined scientific fields of bioinformatics, biotechnology, onco-immunology and data science